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ABSTRACT
Background: Hepatitis B virus (HBV) infection is still reported from adult hemodialysis units.
Objectives: To determine the prevalence of anti-HBs antibody in hemodialysis patients and 
the correlation between levels of anti-HBs antibody with other factors.
Patients and Methods: HBsAg, anti-HBs and anti-HBc antibodies level in 119 hemodialysis pa-
tients were evaluated by enzyme-linked immunosorbent assay.
Results: Seroconversion (anti-HBs antibody >10 IU/L) was found in 22 patients. Minimum pro-
tective antibody level was found in patients aged ≥60 years. Statistically significant correla-
tion was not found between anti-HBs antibody and gender. Ten (8.4%) patients had abnormal 
ALT and/or AST. Prevalence of HBsAg, anti-HBc antibody, HBeAg and anti-HBe antibody were 
found in 8 (6.72%), 24 (25.16%), 2 (1.68%) and 3 (2.52%) patients, respectively.
Conclusions: Periodic assessment of anti-HBs antibody level is strongly recommended in pa-
tients undergoing hemodialysis.
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Background
Hepatitis B virus (HBV) is a DNA virus transmitted percu-
taneously, sexually or prenatally affecting 350–400 million 
persons worldwide. HBV infection globally accounts for one 
million  deaths  annually  from  liver  failure,  cirrhosis,  and 
hepatocellular carcinoma (1-5). Compared with the general 
population, dialysis patients are at high risk of acquiring 
HBV that may be directly exposed to blood products, shared 
hemodialysis (HD) devices and breaching of the skin. HD 
which needs access to the blood circulation, also may lead 
to transmission of HBV between patients, and between pa-
tients and staffs (6). Viral proteins of clinical importance 
include the envelope protein, hepatitis B surface antigen 
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(HBsAg), hepatitis B core antigen (HBcAg) and hepatitis B e 
antigen (HBeAg). Serum HBsAg is considered as a marker of 
chronic HBV infection (7). The detection of anti-HBc and anti-
HBs antibodies denotes a previous infection (8). Anti-HBs an-
tibody levels of > 10 IU/L indicate the immunity. There is an 
inverse correlation between the risk of HBV infection after 
exposure and the maximal anti-HBs response to vaccination, 
(9) with an anti-HBs antibody titer of >100 IU/L conferring 
very effective protection (10, 11).
Objectives
Due to irregular vaccination of hemodialysis patients in 
Bushehr province, southern Iran, at the time of the study, 
this study was carried out to determine the prevalence of HB-
sAg, anti-HBs antibody, anti-HBc antibody, HBeAg and anti-
HBe antibody in HD patients in Bushehr province, southern 
Iran. Correlations between level of anti-HBs antibody with 
age, gender, diabetes mellitus (DM), duration of dialysis and Hepat Mon. 2011;11(3):200-202
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fluctuation of liver function tests (AST and ALT) were also as-
sessed in this study.
 
Patients and Methods
From  September  2004  to  September  2005,  119  patients 
undergoing HD in Bushehr University of Medical Sciences 
affiliated hospitals were screened for HBsAg, anti-HBs and 
anti-HBc  antibodies.  A  questionnaire  was  used  to  collect 
demographic data, date of onset of HD, length of HD ser-
vices and other probable risk factors. History of vaccination 
against HBV was recorded from patient’s medical records. 
Enzyme-linked immunosorbent assays (ELISA, Biokit, Spain) 
was used to measure HBsAg, anti-HBs and anti-H anti-HBs an-
tibody Bc antibodies titers. ELISA reader (Thermolab system, 
Finland) was used to measure the titer of antibody at 450 
nm. The HBsAg-positive samples were then sent to Iranian 
Blood Transfusion Center in Bushehr, southern Iran to be 
screened for HBeAg and anti-HBe antibody using ELISA (Dia-
sorin, Italy). The data were analyzed by SPSS® for Windows® 
(ver 15, Chicago, IL, USA). A p value <0.05 was considered sta-
tistically significant.
Results
A total of 119 HD patients were assessed for HBV serologi-
cal markers of which 44 (37%) were female and 75 (63%) were 
male. Correlation between anti-HBs antibody titer and gen-
der was not statistically significant (p>0.05). The mean ± SD 
age of patients was 48±14 (range: 10–83) years. The patients 
were classified into six groups based on their age and anti-
HBs antibody titer with a cutoff value of 10 IU/L. The preva-
lence of protective antibody titer in two age groups includ-
ing 60–69 and ≥ 70 years were at the lowest level (p = 0.031). 
From the 119 HD patients, 112 (94.1%) had received at least one 
dose of vaccination. The frequencies of patients who had re-
ceived one, two and three doses of vaccine were 78 (69.6%), 19 
(17%) and 15 (13.4%), respectively. The prevalence of anti-HBs 
antibody >10 IU/L and anti-HBs Ab > 100 IU/L were 22 (18.5%) 
and 7 (5.9%), respectively. No anti-HBs antibody-positive pa-
tients was found positive for anti-HBc antibody. Therefore, 
the  positive  anti-HBs  antibody  was  indeed  reflected  im-
munity due to vaccination. An increase in the number of 
vaccination dose, resulted into a rise in the titer of the cor-
responding antibody (Table 1). The prevalence of anti-HBs 
antibody ≥10 IU/L and anti-HBs antibody ≥ 100 IU/L in differ-
ent groups of dialysis patients is shown in Table 2. Thirty-two 
patients had received a complete vaccine dose (3 doses) with 
long period of dialysis (≥ 4 years). Titer of antibody in 32% 
of these patients rose to ≥ 10 IU/L; the rate for those who 
had received only one dose of vaccine was 8.3% (Table 2). Ten 
(8.4%) patients had abnormal ALT (> 31 U/L in women and > 
41 U/L in men) and/or AST (> 31 U/L in women and >37 U/L in 
men). Co-incidence of abnormal ALT and/or AST with anti-
HBs and anti-HBc antibodies were observed in 3 (2.5%) and 
4 (3.3%) patients, respectively. The prevalence of HBsAg, anti-
HBc antibody, HBeAg and anti-HBe antibody were 6.72% (n = 
8), 25.16% (n = 24), 1.68% (n = 2) and 2.52% (n = 3), respectively.
Discussion
An increased risk of exposure to HBV infections is observed 
in patients on chronic HD (12). It has been shown that after 
Table 1. Prevalence of anti-HBs antibody ≥10 IU/L and anti-HBs antibody ≥100 IU/L 
in different doses of vaccination in 112 hemodialysis patients who had received at 
least one dose of vaccine
Number 
of doses 
received
No (%) Anti-HBs 
antibody ≥ 10 
IU/L (%)
Anti-HBs 
antibody ≥ 100 
IU/L (%)
1 78 (69.6) 8 (10) 1 (1)
2 19 (17) 5 (26) 3 (16)
3 15 (13.4) 8 (53) 3 (20)
vaccination, dialysis patients develop lower antibody titers 
compared to healthy individuals, and are unable to main-
tain adequate antibody titers over time (13). Distribution of 
gender in HD patients in the current study was similar to 
that in local and international reports (14-17). Despite a slight 
higher frequency in male, no association was observed with 
gender in this study. Old HD patients had routinely a poorer 
immune response as observed in this study (18-21). Lower an-
tibody production in elderly to vaccines could be due to their 
diminished immune response (22). The present study was in 
keeping with other reports that there was not a significant 
association between presence of DM in HD patients and poor 
immune response (23, 24). In the present study, the frequen-
cy of people with anti-HBs antibody >10 IU/L was lower than 
that reported in other studies from Iran and other countries 
(14-17, 25-28). This can be explained by the fact that only 13.4% 
of HD patients studied had received a complete vaccination 
schedule, hence, antibody titer has not reached a protec-
tive level. Besides, lack of information on the date of previ-
ous vaccination or response to vaccines can interfere with 
accurate interpretation of the results. In this investigation, 
the prevalence of HBsAg was 6.72%. National reports show a 
lower prevalence rate of 3.7% in Semnan, 1.7% in Kashan (29), 
2.4% in Tehran in 2005 (16), and 2.4% in 2008 (29); interna-
tional reports indicate a prevalence ranging from 5.88 % in 
Bahrain and Saudi Arabia (30) to 15.4% in Brazil (31). In a study 
by Alavian, et al, the prevalence of HBsAg has been decreased 
from 3.8% in 1999 to 2.6% in 2006 among HD patients in Iran 
(32). Similar to our findings (25.16%), anti-HBc antibody was 
shown to be 21.5% in southeastern Iran (33). Ferriera, et al, no-
ticed that patients on maintenance HD for more than three 
years had a 2.6 (95% CI: 1.7–4.0) times higher risk of acquiring 
HBV infection compared to those who had undergone HD 
for less than 12 months (34). This correlation was not found 
to be significant for HBV infection in the present study. There 
is a low prevalence rate of positive anti-HBs antibody in HD 
units. Therefore, HD patients should take a complete vac-
cination schedule and be monitored afterwards. In case of 
inadequate antibody titer, these patients should receive an 
additional dose of vaccine.
Number of doses 
received (%)
≥ 10 
IU/L (%)
≥ 100 
IU/L (%) Total
1 2 3
≤ 1 year 40 (90) 4 (10) 0 (0) 4 (8) 0 (0) 44 (39.3)
2 years 22 (71) 3 (10) 6 (19) 7 (23) 2 (7) 31 (27.7)
3 years 5 (42) 6 (50) 1 (8) 3 (20) 1 (7) 12 (10.7)
≥ 4 years 11 (44) 6 (24) 8 (32) 8 (32) 2 (8) 25 (22.3)
Table 2. Prevalence of anti-HBs antibody ≥10 IU/L and anti-HBs antibody ≥100 IU/L 
in different groups of dialysis in 112 patients who had received at least one dose 
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